Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Tombal

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
BJU International|April 12, 2002
Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?B Tombal, N Tajeddine, J-P Cosyns, et al.
Acta Urologica Belgica|September 1, 1994
[Urethral stenosis in children. Apropos of 33 pediatric cases]B Tombal, A Abi Aad, R Opsomer, et al.
BJU International|November 26, 1999
Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancersB Tombal, L De Visccher, J P Cosyns, et al.
ESMO Open|June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancerB Tombal, C N Sternberg, M Hussain, et al.
Clinical Chemistry|March 25, 1998
Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardizationJ L Gala, M Heusterspreute, S Loric, et al.
The Prostate. Supplement|January 1, 1996
Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancerP J Van Cangh, P De Nayer, P Sauvage, et al.
Journal of Endourology|April 1, 1996
Vessels around the ureteropelvic junction: significance and imaging by conventional radiologyP J Van Cangh, S Nesa, M Galeon, et al.
European Radiology|March 5, 2013
MRI for response assessment in metastatic bone diseaseF E Lecouvet, A Larbi, V Pasoglou, et al.
Urology|December 1, 1996
Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSAP J Van Cangh, P De Nayer, L De Vischer, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2014
Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patientsF Moltzahn, J Karnes, P Gontero, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
BJU International|April 12, 2002
Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?B Tombal, N Tajeddine, J-P Cosyns, et al.
Acta Urologica Belgica|September 1, 1994
[Urethral stenosis in children. Apropos of 33 pediatric cases]B Tombal, A Abi Aad, R Opsomer, et al.
BJU International|November 26, 1999
Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancersB Tombal, L De Visccher, J P Cosyns, et al.
ESMO Open|June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancerB Tombal, C N Sternberg, M Hussain, et al.
Clinical Chemistry|March 25, 1998
Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardizationJ L Gala, M Heusterspreute, S Loric, et al.
The Prostate. Supplement|January 1, 1996
Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancerP J Van Cangh, P De Nayer, P Sauvage, et al.
Journal of Endourology|April 1, 1996
Vessels around the ureteropelvic junction: significance and imaging by conventional radiologyP J Van Cangh, S Nesa, M Galeon, et al.
European Radiology|March 5, 2013
MRI for response assessment in metastatic bone diseaseF E Lecouvet, A Larbi, V Pasoglou, et al.
Urology|December 1, 1996
Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSAP J Van Cangh, P De Nayer, L De Vischer, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2014
Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patientsF Moltzahn, J Karnes, P Gontero, et al.
Pageof 6